<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="pola-rchp-hlh-dlbcl-sun">
    <meta name="study:title" content="PB3323 - A single-center pilot study of Pola-RCHP for treating newly diagnosed diffuse large B-cell lymphoma with hemophagocytic lymphohistiocytosis">
    <meta name="study:fileName" content="Abstracts/POLA-RCHP-HLH-DLBCL-SUN.html">
    <meta name="study:cancerTypes" content="DLBCL,LBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="1L">
    <meta name="study:evidenceType" content="Clinical trial">
    <meta name="study:drugs" content="Polatuzumab Vedotin,ADC,Rituximab,Monoclonal Antibody,Chemotherapy,CIT,Pola-RCHP,Ruxolitinib">

    <title>PB3323: Pola-RCHP in 1L DLBCL with HLH (Sun) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css">
</head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PB3323 - Pola-RCHP in 1L DLBCL with Hemophagocytic Lymphohistiocytosis (HLH)</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996-2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0 2.706.39 3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim (N=4)</h4>
                    <p>Newly diagnosed DLBCL with HLH. Aim: Evaluate Pola-RCHP safety & efficacy.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path fill-rule="evenodd" d="M10.5 3.75a.75.75 0 01.75-.75h1.5a.75.75 0 01.75.75V4.5h3A2.25 2.25 0 0118.75 6.75v1.5a2.25 2.25 0 01-2.25 2.25H15.5V12h1.25a.75.75 0 010 1.5H15.5v1.5h.75a.75.75 0 010 1.5H15.5v1.5H18a.75.75 0 010 1.5h-2.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0v-3A2.25 2.25 0 016 14.25v-1.5A2.25 2.25 0 018.25 10.5H9.5V9H8.25A2.25 2.25 0 016 6.75v-1.5A2.25 2.25 0 018.25 3H10.5V3.75zm-1.5 6.75h6V6.75H9V10.5z" clip-rule="evenodd" />
                    </svg>
                    <h4>Intervention</h4>
                    <p>Pola-RCHP (Polatuzumab, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone) x6 cycles, then Rituximab maintenance x2.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path d="M3 13.5a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 13.5zM3 8.25a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 8.25zM3 18.75a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 18.75zM20.25 3a.75.75 0 00-.75.75v16.5a.75.75 0 001.5 0V3.75a.75.75 0 00-.75-.75z" />
                        <path fill-rule="evenodd" d="M9.97 4.28a.75.75 0 01.75-.75H12a.75.75 0 01.75.75v10.174l3.108-3.293a.75.75 0 111.084 1.038l-4.5 4.75a.75.75 0 01-1.084 0l-4.5-4.75a.75.75 0 111.084-1.038L9.97 14.454V4.28z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Efficacy (2/4 Pts Fully Evaluable)</h4>
                    <p>ORR: <span class="highlight-value">100%</span> (Both CR at C8). HLH markers normalized in all 4 Pts.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm-.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Safety & Conclusion</h4>
                    <p>Good tolerability. G4 neutropenia (1 Pt). Effective HLH control & DLBCL remission. Promising short-term outcomes.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PB3323 - A single-center pilot study of Pola-RCHP for treating newly diagnosed diffuse large B-cell lymphoma with hemophagocytic lymphohistiocytosis</h1>
            <p class="abstract-sub-header">Jianai Sun, Xiaolong Zheng, Jie Jin, Hongyan Tong, Wanzhuo Xie, De Zhou</p> <p class="abstract-meta-info mt-2">EHA 2025 Congress | Abstract #PB3323 | Publication Only</p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Hemophagocytic lymphohistiocytosis (HLH) is a cytokine-mediated hyperinflammatory syndrome.</li>
                        <li>A subset of diffuse large B-cell lymphoma (DLBCL) patients presents with HLH initially, often associated with poor prognosis.</li>
                        <li>Pola-RCHP (polatuzumab vedotin + R-CHP) has shown significant efficacy and favorable safety in newly diagnosed DLBCL.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <p class="text-sm mb-1">To evaluate the safety and therapeutic efficacy of Pola-RCHP in newly diagnosed DLBCL patients complicated by HLH.</p>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li>Single-center pilot study.</li>
                        <li>Enrollment: August 1, 2024 - December 31, 2025.</li>
                        <li>Patients (N=4): DLBCL presenting with HLH, meeting ≥5 HLH-2004 criteria. DLBCL diagnosed after HLH treatment.</li>
                        <li>HLH pre-treatment: Corticosteroids (2 Pts), Ruxolitinib + Corticosteroids (2 Pts).</li>
                        <li>Response assessment: 2014 Lugano criteria. Adverse Events (AEs): CTCAE v5.0.</li>
                    </ul>
                    <div class="study-design-schema">
                        <h3 class="schema-title">Pola-RCHP Treatment Regimen</h3>
                        <div class="schema-enrollment">
                            <strong>Eligible Patients (N=4)</strong>
                            <span>Newly Diagnosed DLBCL with HLH</span>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-phase-group">
                            <div class="schema-phase">
                                <strong>Pola-RCHP (q21d x 6 cycles)</strong>
                                <span>Polatuzumab vedotin: 1.8 mg/kg IV (D2)</span>
                                <span>Rituximab: 375 mg/m² IV (D1)</span>
                                <span>Cyclophosphamide: 750 mg/m² IV (D2)</span>
                                <span>Doxorubicin: 150 mg/m² IV (D2)</span>
                                <span>Prednisone: 100 mg PO (D2-6)</span>
                            </div>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                         <div class="schema-phase-group">
                            <div class="schema-phase">
                                <strong>Maintenance (x2 cycles)</strong>
                                <span>Rituximab monotherapy</span>
                            </div>
                        </div>
                        <div class="schema-assessment-points">
                           <span>Response (Lugano 2014)</span>
                           <span>Safety (CTCAE v5.0)</span>
                           <span>HLH Markers</span>
                        </div>
                    </div>
                     <p class="footnote-text mt-2">Median follow-up: 150.5 days (range, 47-197).</p>
                </div>
            </div>

            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Patient Characteristics (N=4)</h2>
                    <div class="table-container">
                        <table>
                            <thead>
                                <tr><th>Characteristic</th><th>Value</th></tr>
                            </thead>
                            <tbody>
                                <tr><td>Median Age, years (range)</td><td>62 (49-72)</td></tr>
                                <tr><td>Gender, Male n (%)</td><td>3 (75.0%)</td></tr>
                                <tr><td>HANS Classification<sup>a</sup>, n (%)</td><td></td></tr>
                                <tr><td class="pl-6">non-GCB</td><td>3 (75%)</td></tr>
                                <tr><td class="pl-6">GCB</td><td>1 (25%)</td></tr>
                                <tr><td>Richter Transformation to DLBCL, n (%)</td><td>1 (25%)</td></tr>
                                <tr><td>Ann Arbor Stage III-IV, n (%)</td><td>4 (100%)</td></tr>
                                <tr><td class="pl-6">Stage IVB (from text)</td><td>4 (100%)</td></tr>
                                <tr><td>B Symptoms, n (%)</td><td>4 (100%)</td></tr>
                                <tr><td>ECOG PS<sup>b</sup> 2-4, n (%)</td><td>4 (100%)</td></tr>
                                <tr><td>IPI Score<sup>c</sup>, n (%)</td><td></td></tr>
                                <tr><td class="pl-6">Score 5</td><td>2 (50%)</td></tr>
                                <tr><td class="pl-6">Score 4</td><td>1 (25%)</td></tr>
                                <tr><td class="pl-6">Score 3</td><td>1 (25%)</td></tr>
                                <tr><td>Bone Marrow Involvement, n (%)</td><td>4 (100%)</td></tr>
                                <tr><td>Extranodal Sites > 1, n (%)</td><td>2 (50%)</td></tr>
                                <tr><td colspan="2" class="font-semibold pt-3">Criteria for Hemophagocytic Lymphohistiocytosis</td></tr>
                                <tr><td>Fever<sup>d</sup>, n (%)</td><td>4 (100%)</td></tr>
                                <tr><td>Splenomegaly, n (%)</td><td>4 (100%)</td></tr>
                                <tr><td>Blood Cytopenia (≥2 lineages), n (%)</td><td>4 (100%)</td></tr>
                                <tr><td class="pl-6">Neutrophils, median (range) x10<sup>9</sup>/L</td><td>1.81 (0.81-3.61)</td></tr>
                                <tr><td class="pl-6">Hemoglobin, median (range) g/L</td><td>97.50 (46.00-145.00)</td></tr>
                                <tr><td class="pl-6">Platelet, median (range) x10<sup>9</sup>/L</td><td>57.00 (4.00-152.00)</td></tr>
                                <tr><td>Triglycerides >3.0 mmol/L, n (%)</td><td>3 (75%)</td></tr>
                                <tr><td>Fibrinogen &lt;1.5 g/L, n (%)</td><td>0 (0%)</td></tr>
                                <tr><td>Bone Marrow Hemophagocytosis, n (%)</td><td>3 (75%)</td></tr>
                                <tr><td>Ferritin >500 µg/L, n (%)</td><td>4 (100%)</td></tr>
                                <tr><td class="pl-6">Ferritin, median (range) µg/L</td><td>2988.1 (1581.2-7501)</td></tr>
                                <tr><td>Low NK Cells<sup>e</sup> Activity, n (%)</td><td>2 (50%)</td></tr>
                                <tr><td>High sCD25<sup>f</sup> (>6400 pg/ml), n (%)</td><td>4 (100%)</td></tr>
                                <tr><td class="pl-6">sCD25, median (range) pg/ml</td><td>15025 (13670-52566)</td></tr>
                            </tbody>
                        </table>
                    </div>
                    <div class="footnote-text">
                        <p><sup>a</sup>Hans: Hans Classification for DLBCL. <sup>b</sup>ECOG: Eastern Cooperative Oncology Group Performance Status. <sup>c</sup>IPI: International Prognostic Index. <sup>d</sup>Fever: Body temperature >38.5°C for >1 week. <sup>e</sup>NK cells: Natural Killer cells. <sup>f</sup>sCD25: Soluble CD25.</p>
                         <p>Median age from abstract text: 60.5 years.</p>
                    </div>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Efficacy Results (N=4)</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2 mb-3">
                        <li><strong>For 2 Pts who completed 8 cycles (6 Pola-RCHP + 2 R-mono):</strong>
                            <ul class="list-circle list-inside ml-4">
                                <li>PET-CT at 4th cycle: Both Partial Remission (PR).</li>
                                <li>PET-CT at 8th cycle: Both Complete Remission (CR).</li>
                            </ul>
                        </li>
                        <li><strong>For 2 Pts who completed 2-3 cycles:</strong>
                            <ul class="list-circle list-inside ml-4">
                                <li>HLH-related markers normalized.</li>
                                <li>No evidence of tumor on ultrasound or bone marrow aspiration (comprehensive PET-CT assessment pending).</li>
                            </ul>
                        </li>
                        <li>Platelet counts normalized within 3-14 days.</li>
                        <li>Ferritin levels returned to normal (&lt;500 ng/mL) after 1-4 cycles.</li>
                    </ul>
                    <div class="chart-container mb-6">
                        <svg id="polaRchpHlhResponseChart" width="350" height="280"></svg>
                        <div id="polaRchpHlhResponseLegend" class="legend"></div>
                    </div>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Safety Summary (N=4)</h2>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Regimen was generally well-tolerated.</li>
                        <li>One patient experienced Grade 4 neutropenia with fever and oropharyngeal Candida infection, which improved with colony-stimulating factor and antimicrobial therapy.</li>
                        <li>No Grade 4 thrombocytopenia or bleeding events were observed.</li>
                    </ul>
                </div>
            </div>
        </div>

        <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>Pola-RCHP regimen exhibited a high response rate and promising short-term survival outcomes in patients with HLH-onset DLBCL.</li>
                <li>It effectively achieved rapid control of HLH-related symptoms and induced deep remission of DLBCL.</li>
                <li>The regimen demonstrated good tolerability.</li>
                <li>Further studies with larger cohorts are warranted to validate the long-term efficacy and safety.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <h2 class="abstract-section-title">Abbreviations</h2>
            <p>ADC, Antibody-Drug Conjugate; AE, Adverse Event; BID, Twice a day; CR, Complete Remission; CTCAE, Common Terminology Criteria for Adverse Events; D, Day; DLBCL, Diffuse Large B-Cell Lymphoma; ECOG PS, Eastern Cooperative Oncology Group Performance Status; EOT, End of Treatment; GCB, Germinal Center B-cell like; GCSF, Granulocyte Colony-Stimulating Factor; HLH, Hemophagocytic Lymphohistiocytosis; IPI, International Prognostic Index; IV, Intravenous; kg, Kilogram; mg, Milligram; m², Square Meter; ng/mL, Nanograms per milliliter; NK, Natural Killer; ORR, Overall Response Rate; PET-CT, Positron Emission Tomography-Computed Tomography; PO, Per Os (by mouth); Pola, Polatuzumab vedotin; PR, Partial Remission; Pt(s), Patient(s); q21d, Every 21 days; R-CHP, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone; sCD25, Soluble CD25.</p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">
                Sun J, Zheng X, Jin J, et al. A single-center pilot study of Pola-RCHP for treating newly diagnosed diffuse large B-cell lymphoma with hemophagocytic lymphohistiocytosis. Abstract #PB3323 presented at European Haematology Association (EHA) June 12–15, 2025, Milan, Italy.
            </p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA 2025 Congress | Abstract #PB3323 | Abstract Release: 05/14/2025 | Presentation: 06/12/2025</p>
            <p>For Research & Informational Purposes Only.</p>
        </div>
    </div>

    <script defer src="abstract_features.js"></script>
    <script>
        function drawResponseChartPolaRchpHlh(containerId, legendContainerId) {
            const chartData = {
                // For the 2 patients who completed 8 cycles:
                // PET-CT at 4th cycle showed PR, and at 8th cycle showed CR for these patients.
                // So, at 8th cycle, both (100%) achieved CR.
                keys: ["CR"], // Only CR as both achieved it
                values: {
                    CR: 100.0, // 2 out of 2 patients
                    PR: 0.0,
                    "Other": 0.0
                },
                colors: ["var(--sobi-teal)", "var(--sobi-yellow)", "var(--sobi-medium-gray-text)"],
                orr: 100.0 // Overall Response Rate for these 2 patients
            };
            const chartTitle = "Response at 8th Cycle (N=2 Evaluable Pts)";

            const svg = d3.select(containerId);
            const legendContainer = d3.select(legendContainerId);

            svg.selectAll("*").remove();
            legendContainer.selectAll("*").remove();

            let containerWidth = 350; // Default width
            const chartWrapper = svg.node() ? svg.node().closest('.chart-container') : null;
            if (chartWrapper) {
                // Adjust width based on container, but not too small
                containerWidth = Math.max(chartWrapper.getBoundingClientRect().width * 0.85, 280);
            }
            
            const svgWidth = containerWidth;
            const svgHeight = +svg.attr("height"); // Height from attribute

            const margin = { top: 40, right: 20, bottom: 30, left: 50 };
            const chartWidth = svgWidth - margin.left - margin.right;
            const chartHeight = svgHeight - margin.top - margin.bottom;

            if (chartWidth <= 0 || chartHeight <= 0) return;

            const g = svg.append("g")
                .attr("transform", `translate(${margin.left},${margin.top})`);

            const categories = ["Response"];
            const stack = d3.stack().keys(chartData.keys.filter(key => chartData.values[key] > 0)); // Filter out zero values for stacking
            const stackedData = stack([chartData.values]);

            const xScale = d3.scaleBand()
                .domain(categories)
                .range([0, chartWidth])
                .padding(0.6); // Adjust padding for single bar

            const yScale = d3.scaleLinear()
                .domain([0, 100]) // Percentage scale
                .range([chartHeight, 0]);

            g.append("g")
                .attr("transform", `translate(0,${chartHeight})`)
                .call(d3.axisBottom(xScale).tickValues([])) // No ticks for "Response" category label
                .select(".domain").remove();

            g.append("g")
                .call(d3.axisLeft(yScale).ticks(5).tickFormat(d => d + "%"))
                .selectAll("text")
                .attr("class", "axis-text")
                .style("font-size", "10px");
            
            g.append("g")			
                .attr("class", "grid")
                .call(d3.axisLeft(yScale)
                    .ticks(5)
                    .tickSize(-chartWidth)
                    .tickFormat("")
                )
                .selectAll("line")
                .style("stroke", "#e0e0e0")
                .style("stroke-opacity", "0.7");

            const color = d3.scaleOrdinal()
                .domain(chartData.keys)
                .range(chartData.colors);

            g.selectAll(".serie")
                .data(stackedData)
                .enter().append("g")
                  .attr("class", "serie")
                .selectAll("rect")
                .data(d => d)
                .enter().append("rect")
                    .attr("x", d => xScale(categories[0]))
                    .attr("y", d => yScale(d[1]))
                    .attr("height", d => yScale(d[0]) - yScale(d[1]))
                    .attr("width", xScale.bandwidth())
                    .attr("fill", (d, i, nodes) => {
                        const seriesKey = d3.select(nodes[i].parentNode).datum().key;
                        return color(seriesKey);
                    })
                    .attr("rx", 3).attr("ry", 3);
            
            stackedData.forEach((series) => {
                series.forEach((d) => {
                    const y0 = d[0];
                    const y1 = d[1];
                    const percentage = y1 - y0;
                    if (percentage > 5) { // Threshold for displaying label
                        g.append("text")
                            .attr("class", "chart-label")
                            .attr("x", xScale(categories[0]) + xScale.bandwidth() / 2)
                            .attr("y", yScale(y0 + percentage / 2) + 4)
                            .attr("text-anchor", "middle")
                            .style("fill", "white") // Assuming dark bar color
                            .style("font-size", "10px")
                            .style("font-weight", "bold")
                            .text(`${percentage.toFixed(0)}%`);
                    }
                });
            });
            
            svg.append("text")
                .attr("x", svgWidth / 2)
                .attr("y", margin.top / 2 + 5)
                .attr("text-anchor", "middle")
                .style("font-size", "13px")
                .style("font-weight", "600")
                .style("fill", "var(--sobi-dark-blue)")
                .text(chartTitle);

            const legendData = chartData.keys.filter(key => chartData.values[key] > 0).map(key => ({
                label: `${key} (${chartData.values[key].toFixed(0)}%)`,
                color: color(key)
            }));

            const legendItems = legendContainer.selectAll(".legend-item")
                .data(legendData).enter().append("div").attr("class", "legend-item");
            legendItems.append("div").attr("class", "legend-color-box").style("background-color", d => d.color);
            legendItems.append("span").text(d => d.label);
        }

        function debounce(func, wait) {
            let timeout;
            return function executedFunction(...args) {
                const later = () => {
                    clearTimeout(timeout);
                    func(...args);
                };
                clearTimeout(timeout);
                timeout = setTimeout(later, wait);
            };
        };

        const debouncedDrawChart = debounce(() => drawResponseChartPolaRchpHlh("#polaRchpHlhResponseChart", "#polaRchpHlhResponseLegend"), 250);
        
        window.addEventListener('resize', debouncedDrawChart);
        
        document.addEventListener('DOMContentLoaded', () => {
            debouncedDrawChart();
        });
        // Fallback if DOMContentLoaded already fired
        if (document.readyState === "complete" || document.readyState === "interactive") {
             setTimeout(debouncedDrawChart, 0); 
        }
    </script>
</body>
</html>
